logo
When an Air India flight crashed into a medical campus, surviving doctors rushed to save lives

When an Air India flight crashed into a medical campus, surviving doctors rushed to save lives

Yahoo17-06-2025

AHMEDABAD, India — Navin Chaudhary had just begun eating his meal when a loud bang startled him. He turned back to see a massive fire taking over the dining area where he and other trainee doctors had assembled for lunch.
The blaze approaching him, he rushed toward a window and jumped.
From the ground, looking upward, the sight of the Air India plane's tail cone hanging from the burning building propelled Chaudhary and fellow medical students into action.
'There was fire and many were injured,' said Chaudhary.
He said he felt lucky to survive but knew he had a task at hand. He rushed to the hospital's intensive care unit, where the injured, most of whom had burns, were wheeled in on stretchers.
'I felt that as a doctor I could save someone's life,' he said. 'I was safe. So I thought, whatever I can do, I should.'
At least 270 died when the Air India flight crashed into the campus of a medical college in Ahmedabad shortly after takeoff on Thursday. Only one passenger among the 242 aboard survived. At least 29 others on the ground, including five medical students inside the hostel, were also killed.
Many believe that the death toll would have been higher if it had not been for the intervention of the trainee doctors and students who emerged from the smouldering hostel and rushed to save their colleagues.
Akshay Zala, a senior medical student, said the crash felt 'like an earthquake.'
'I could hardly see anything as thick plumes of smoke and dust engulfed everything. I was barely able to breathe,' he said.
Zala rushed to safety, running through dust and smoke. He cleaned and bandaged a wound on his left leg then joined others at the medical college's trauma center to treat the injured.
On Monday, the crash site teemed with excavators and workers clearing the debris. Officials inspected the building in search of clues that could enable the investigators to figure out what led to the tragedy.
Barely a kilometer (less than a mile) away, trainee doctors who survived one of India's worst aviation disasters were still working to identify the victims through DNA testing.
Indian authorities have so far handed over the remains of 47 victims The bodies of 92 others have also been identified through DNA matching and will be transferred to relatives soon.
College dean Minakshi Parikh said that many of the doctors who pulled their colleagues out of the debris, later that day went back to their duties to save as many lives as they could. 'They did that and that spirit has continued till this moment,' Parikh said.
Images of the hostel's dining area shortly after the crash showed parts of the aircraft and pieces of luggage strewn on the floor. Dining plates still containing food lay on the few dusty tables that were left intact by the impact.
'So that is human nature, isn't it? When our own people are injured, our first response is to help them,' Parikh said. 'So the doctors who managed to escape ... the first thing that they did was they went back in and dug out their colleagues who were trapped inside.'
'They might not even have survived because the rescue teams take time coming,' she added.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

Yahoo

timean hour ago

  • Yahoo

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

SAN FRANCISCO and SUZHOU, China, June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, held its Oncology R&D Day, unveiling its forward-looking strategy centered on dual innovation in next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) technologies. This strategic focus aims to redefine the standards of cancer treatment and propel Innovent toward becoming a global, premier biopharmaceutical leader. The event drew over 500 participants, including leading oncology key opinion leaders (KOLs), principal investigators, analysts, and global investors, signaling strong engagement with Innovent's transformative vision for the future of oncology. "Over the past decade, Innovent has been at the forefront of China's biopharmaceutical evolution—pioneering the PD-1 immunotherapy era and building China's leading oncology brand, with over 3 million cancer patients treated with our therapies," said Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent. "We are entering a new chapter focused on global innovation, powered by a robust pipeline and dual innovation of next-generation IO and next-generation ADC. Our recent presence at the 2025 ASCO with eight oral presentations highlights the strength and global competitiveness of our R&D. But this is only the beginning. With a clear vision to advance at least five pipeline assets into MRCT Phase 3 by 2030, we are committed to delivering innovative, high-quality, and accessible cancer treatments to patients worldwide." Dual Innovation to Unlock the Future of Oncology: Next-gen IO + Next-gen ADC At the core of Innovent's oncology strategy lies the dual engines of next-generation immunotherapy (IO) and next-generation antibody-drug conjugates (ADC), supported by deep insights in cancer biology and differentiated technology platforms. "We are harnessing deep cancer biology insights, advanced antibody and protein engineering, and differentiated ADC linker-payload technologies to develop broader-spectrum, more potent, and less toxic therapies aimed at transforming the oncology treatment paradigm," said Dr. Zhou Hui, SVP of Innovent Oncology R&D. "Our strategy is designed to target some of the toughest challenges in cancer care, including drug resistance, cold tumors, and improve the efficacy of current IO treatment, while bringing new hope to patients worldwide." Global R&D Roadmap: a Clear, Stepwise Development Strategy Innovent's pipeline is guided by a rational, phased IO+ADC combination strategy designed to address tumor heterogeneity and immune escape, evolving through three stages: Next-gen IO + Chemotherapy: to redefine the IO cornerstone Next-gen IO + mAb-ADC / bispecific ADC: to cover expansive tumor types and treatment lines Next-gen IO + Dual-Payload ADC (dpADC): to unlock full potential of IO+ ADC synergy, and reshape cancer treatment Currently its oncology pipeline features nearly 10 next-generation molecules in global development, with multi-regional trials actively underway in the U.S., EU, and Asia. The company also continues to invest in global R&D infrastructure, supported by R&D hubs in Shanghai and San Francisco and antibody and ADC manufacturing capacity exceeding 140,000L. Innovent is rapidly expanding its global innovation footprint, with a 2030 goal to advance at least five pipeline assets into global MRCT Phase 3 trials. Key potential candidates includes: IBI343: innovative CLDN18.2 ADC with site-specific conjugation and a TOPO1 inhibitor payload, demonstrating significant survival benefits in both GC and PDAC IBI363: PD-1/IL-2α-bias fusion protein as next-gen IO to redefine cancer treatment and expand the boundaries of IO responsiveness IBI3009: DLL3 ADC in collaboration with Roche IBI3003: tri-specific T-cell engager targeting BCMA/GPRC5D/CD3 for multiple myeloma IBI3001: EGFR/B7H3 ADC with two synergetic targets covering multiple potential indications IBI3020: CEACAM5 dual-payload ADC as globally the first to enter clinical phase IBI363: Next-Gen IO Redefining Cancer Immunotherapy IBI363 is a global first-in-class PD-1/IL-2α-bias fusion protein, featuring a differentiated molecular design and a dual immune activation mechanism. Emerging clinical data strongly support its mechanism of action in reinvigorating and expanding tumor-specific T cells (TSTs). At ASCO 2025, IBI363 demonstrated breakthrough potential in three hard-to-treat tumor types, with a long tailing effect in prolonged survival benefits: Immune-resistant NSCLC (squamous & Adeno): boosted response rate and extended PFS reflects strong immune activation; median overall survival (mOS) up to 17.5 months in 1.5 mg dose cohorts, 12-month OS rate exceeding 70% for 3 mg dose cohorts, and benefit observed even in PD-L1 low expressers Later-line CRC (3L+): mOS of 16.1 months in monotherapy and only 17.8% OS events occurred in combination with bevacizumab with 9.4 months follow-up, outperforming historical benchmarks Immune-resistant melanoma (mucosal/acral subtypes): confirmed overall response rate (cORR) 23%, median duration of response (mDoR) 14 months, and median OS 14.7 months, showing unprecedented positive response and a long-lasting immunologic tailing effect With two Breakthrough Therapy Designations from the NMPA CDE, two Fast Track Designations from the FDA, IBI363 is advancing rapidly toward registrational development. The first head-to-head trial vs. pembrolizumab in mucosal and acral melanoma was initiated. Meanwhile, IBI363 is in preparation for registrational trails in IO-treated squamous NSCLC, and third-line MSS colorectal cancer. Additional trails for first-line and other solid tumors also under exploration in ongoing PoC studies. High-Potency, Low-toxicity ADC Platforms Synergizing with IO for Broad Indication Coverage Innovent is rapidly advancing its next-gen ADC pipeline, including: IBI343 (CLDN18.2 ADC): first in PDAC to demonstrate long-term survival benefits (mOS 12.1 months in 2L) IBI3001 (EGFR/B7H3 ADC): dual-targeted ADC with broad potential in solid tumors IBI3020 (CEACAM5 dual payload ADC): designed for high efficacy and low toxicity in treatment-resistant tumors These programs leverage proprietary payloads and linkers, optimized for lower toxicity and high potency, and are poised to synergize with Innovent's IO agents to address broader and deeper indications. Innovent Academy: R&D Engine to Drive Global Innovation Innovent Academy is the company's discovery engine for driving global innovation. The Academy continues to expand its platforms in IO, ADC, T-cell engagers, and cytokines, firmly establishing its leadership in next-gen oncology discovery and translational science to generate 6–8 novel molecules per year. Specifically, for next-gen IO and next-gen ADC dual upgradation, Innovent Academy focuses on: diversified antitumor mechanisms to integrate TME modulation and optimize IO efficacy; dual targeting approaches to overcome tumor heterogeneity and drug resistance. This framework allows Innovent to systematically escalate efficacy and broaden tumor applicability, laying the foundation for first-in-class and best-in-class combination regimens for cancer treatments. Catalyzing China's Role in Global Oncology Innovation Leading oncology KOLs and principal investigators (PIs) delivered keynote speeches, reflecting on a pivotal moment for China's biotech industry. They emphasized that China's innovation, which is driven by rising translational capabilities, expanding global talent pools, and patient-centric trial execution, has entered a "Deepseek" moment, one where Chinese-discovered drugs can lead global standards, not just follow them. "What we're witnessing is a profound shift," said one keynote speaker. "Innovent's next-generation IO programs like IBI363, with a clear global-first design, and ADC platforms targeting previously untreatable populations, show that Chinese biotech is poised to influence—not just participate in—the next global oncology paradigm." The enthusiastic response from investors and KOLs underscores growing confidence in China-originated oncology innovation and reaffirms Innovent's position as it enters a new era of global innovation with a vision to become a global premier biopharmaceutical leader. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications (NDA) under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: 1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). 2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. View original content to download multimedia: SOURCE Innovent Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Thailand was the first country in Asia to legalize marijuana. Things didn't go as planned
Thailand was the first country in Asia to legalize marijuana. Things didn't go as planned

CNN

time17 hours ago

  • CNN

Thailand was the first country in Asia to legalize marijuana. Things didn't go as planned

CNN — Three years since Thailand became the first country in Asia to decriminalize cannabis, the government this week imposed new rules designed to rein in the country's ' green rush.' As of Thursday, customers need a doctor's prescription to buy cannabis — effectively restricting consumption of the plant to medical and health purposes only. Thailand's public health minister told CNN on Wednesday he hopes to eventually recriminalize cannabis as a narcotic, in what would be a major reversal from Thailand's liberal approach since declassification, which saw a boom of dispensaries and weed cafes opening across the country, particularly in tourist areas. 'This must be clearly understood: cannabis is permitted for medical use only,' Public Health Minister Somsak Thepsutin told CNN. Medical certificates and a ban on advertising The new rules from Thailand's Health Ministry aim to enforce the regulation of cannabis as a controlled herb. That means licensed cannabis shops can now only sell to customers with a medical prescription. They are also required to keep detailed sales records and face regular inspections by authorities, Somsak said. New rules also put stricter controls on growers and farmers, ban commercial advertising and prohibit cannabis from being sold in vending machines or online. More than 18,000 licensed cannabis shops across the country will have to adapt or risk closing. Penalties for sellers caught violating the new rules include up to one year in prison or a fine of 20,000 baht ($620), though the health ministry is proposing new legislation that would significantly increase this. The ban on advertising may also dramatically change the landscape of tourist hotspots such as Khao San Road in the capital Bangkok, or beach towns like Pattaya, where hundreds of cannabis shops and cafes line the streets with their green neon signs, cannabis-shaped inflatables and catchy slogans enticing tourists to get high. Now, tourists and locals will need a doctor's certificate from Thailand or their home country to purchase cannabis buds to treat certain conditions such as nausea from chemotherapy, drug-resistant epilepsy or nerve pain. 'We want to tell tourists they are welcome to enjoy Thailand's culture and nature — but Thailand should not be seen as a destination for recreational cannabis use,' Somsak said. Why have the new rules been introduced? Medical marijuana has been legal in Thailand since 2018, but decriminalization in 2022 meant it was no longer a crime to grow and trade marijuana or hemp products, or to use any parts of the plant to treat illnesses — a major move in a region notorious for harsh penalties towards illegal drugs. Following legalization, the government intended to regulate the industry. But a legal vacuum emerged when this failed to materialize, and recreational use exploded across the kingdom, particularly in areas popular with foreigners. Thousands of cannabis dispensaries sprang up, as well as other cannabis-themed businesses like weed cafes, hemp spas and places offering beauty treatments. Cities like Chiang Mai and Bangkok have even held weed festivals, and decriminalization has been a major draw for tourists. One such festival in Bangkok earlier this month boasted an appearance by Mike Tyson, who has launched his own brand of boxing glove- and ear-shaped cannabis gummies. A 2022 report released by Thailand's Ministry of Commerce estimated the industry could be worth $1.2 billion by 2025, though Somsak said there is currently 'no clear estimate' of the industry's value 'due to unregulated transactions.' Somsak said the new rules help plug that legal vacuum and prevent misuse. 'We are not shutting down cannabis shops, but we are prioritizing medical regulation,' he said. 'Revenue may dip at first, but considering the social harm caused by unregulated use, the change is necessary … responsible, law-abiding businesses will remain stable and continue operating.' Social impacts and smuggling Those in support of greater regulation say the industry has grown out of control, and cited health concerns, cannabis use among children, and addiction, while complaints of tourists smoking in the street are reportedly growing on the Thai islands. On the holiday island of Phuket, a plan has been proposed that would establish zones restricting where cannabis could be bought and sold. 'Right now, cannabis addiction is rising and has become a social issue. It affects children, causes nuisance from unwanted odors,' said Somsak. 'Public safety must come first… the current cannabis industry is made up of scattered, unregulated shops.' Adding to the issue, cannabis smuggling has soared since legalization. Several high-profile cases involving young, British women have made headlines this year, all originating in Thailand. The issue got so bad that British and Thai authorities formed a joint task force to halt the increase in drugs being smuggled out by tourists and by mail from Thailand to the UK, with Thailand enforcing stricter screening measures at its borders. Between October 2024 and March 2025, more than 800 cannabis smugglers were arrested and over nine metric tons of cannabis were seized, according to the British government. Disrupting the industry Cannabis advocates have argued that the boom across Thailand has helped many Thais, from farmers to small business owners and workers behind the counter. Some sellers are now scrambling to understand what the new regulations will mean for their business. 'The lack of clarity in the law has already caused worry,' said Ake Khattiyadamrong, a cannabis shop owner in eastern Thailand's Chonburi province. 'It's a real shame — Thailand was actually one of the first countries in the world to recognize the benefits of cannabis and legalize it. But once it was legalized, state officials failed to follow through. 'There was no real effort to educate the public. The ministerial regulations that were issued weren't seriously enforced either.' Cannabis advocates say the new regulations won't stop smuggling or unlicensed growers, and risk driving up corruption. 'This is a knee-jerk reaction to supposedly addressing the smuggling issue,' said Kitty Chopaka, a longtime cannabis activist with the Writing Thailand's Cannabis Future Network advocacy group, which pushes for fair access. Chopaka argues that many shops are operating without licenses and sell products such as gummies and edibles that are technically illegal though readily available. 'The police don't shut them down,' she said. If the government enforced the 'rules and laws that currently exist, the issue that they are now saying needs to be fixed wouldn't have existed,' she added. Ake, the shop owner, said requiring a doctor's note to purchase cannabis will not stop people from buying for recreational purposes. 'Everyone knows medical certificates can be bought, so this just creates a new revenue stream for certain doctors … It burdens consumers with extra costs for accessing cannabis, especially during Thailand's current economic struggles and global economic issues,' he said. Ake welcomes regulations that create stability in the industry but wants to see clear, well-rounded laws that are fair to everyone. 'Everything must be traceable and truly safe. I believe that's the core principle. It's not about selling cheap, illegal products. Those can't guarantee user safety,' he said. Since legalization, overproduction of cannabis has saturated the market and driven down prices so cannabis sellers were already taking a hit to their earnings. 'There's not enough sales, the cost of weed is very cheap, and people who live here buy directly from the farms,' said Chopaka, who recently had to close her shop due to low prices and undercutting from bigger sellers. There have been several attempts to pass legislation regulating the cannabis industry. The ruling Pheu Thai Party proposed criminalizing the drug again last year but faced opposition from its coalition partner the Bhumjaithai Party, which spearheaded the original legalization. The latest push from Somsak comes after Bhumjaithai pulled out of the coalition government last week. He said the new regulations are just a first step — but acknowledged getting a bill through parliament will take time. 'This isn't a fixed policy that can't be changed,' he said. 'Without legal control, investment or business operations — no matter the country — must be cautious. If the investment is related to narcotics or controlled substances, there must be clear laws.' But Chopaka fears the new regulations will only make it harder for the smaller farmers to survive. 'I want to see fair access. I want to see rules that make sense,' she said.

Billionaire's death after swallowing bee raises questions about rare cardiac reaction
Billionaire's death after swallowing bee raises questions about rare cardiac reaction

Yahoo

timea day ago

  • Yahoo

Billionaire's death after swallowing bee raises questions about rare cardiac reaction

On June 12, a prominent billionaire from India, Sunjay Kapur, died suddenly at the age of 53 in Windsor, England, according to multiple reports. Kapur was the chairman of Sona Comstar, an Indian automotive components manufacturer. His close friend, business consultant Suhel Seth, confirmed Kapur's death in a post on X that same day. Man's Blood Used To Create Antivenom For 19 Deadly Snakes "Deeply saddened at the passing of @sunjaykapur: he passed away earlier today in England: a terrible loss and deepest condolences to his family and to his colleagues @sonacomstar …Om Shanti," Seth wrote. In the following days, it was revealed that Kapur died while playing polo. Multiple outlets reported that he collapsed after swallowing a bee mid-match, potentially triggering a fatal heart attack. Read On The Fox News App No official source for the billionaire confirmed that a bee caused the heart attack. Fox News Digital reached out to Sona Comstar for comment. "It's not possible to comment with any specificity about this particular case without a thorough review of the forensics," Dr. Nishant Kalra, an Ohio cardiologist and regional chief medical officer at VitalSolution — an Ingenovis Health company that offers cardiovascular and anesthesiology services to hospitals — told Fox News Digital. Poison Fruit In 'White Lotus' Comes From 'Suicide Tree' Swallowing a bee can, in very rare cases, precipitate a heart attack, he confirmed — "but only through specific mechanisms." The primary risk is not from the act of swallowing itself, but from the possibility of a bee sting to either the upper airway or the oropharynx (the part of the mouth that includes the back of the tongue, tonsils and soft palate), which can introduce venom into the body, according to Kalra. If the individual is allergic, this can trigger anaphylaxis, which may cause "profound hypotension, arrhythmias or even acute coronary syndromes," Kalra said — a phenomenon known as Kounis syndrome. This syndrome can result from a coronary event (any adverse medical event related to the coronary arteries, which supply blood to the heart) occurring in combination with anaphylactic or allergic reactions. This can pose a risk even to individuals who do not have pre-existing coronary artery disease. The American Academy of Allergy, Asthma & Immunology notes that cardiac anaphylaxis can cause reduced blood flow to the heart (myocardial ischemia) and irregular heartbeats (arrhythmias) when triggered by an allergy to insect venom. Click Here To Sign Up For Our Health Newsletter However, these cases are incredibly rare, according to experts. "The general population should not be concerned about this as a common risk," Kapur told Fox News Digital. "Fatal cardiac events following bee stings are rare and typically occur in individuals with known venom hypersensitivity or underlying cardiac disease." For more Health articles, visit Most bee stings, even in the oropharynx, result in local reactions, though airway compromise is a concern if significant swelling occurs, he added. Those who experience allergic symptoms following a sting should seek immediate medical article source: Billionaire's death after swallowing bee raises questions about rare cardiac reaction

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store